154 related articles for article (PubMed ID: 10801059)
21. beta-Glucosidase inhibition in murine peritoneal macrophages by conduritol-B-epoxide: an in vitro model of the Gaucher cell.
Newburg DS; Yatziv S; McCluer RH; Raghavan S
Biochim Biophys Acta; 1986 Jun; 877(1):121-6. PubMed ID: 3087427
[TBL] [Abstract][Full Text] [Related]
22. Ethanol-induced changes in the content of triglycerides, ceramides, and glucosylceramides in cultured neurons.
Saito M; Saito M; Cooper TB; Vadasz C
Alcohol Clin Exp Res; 2005 Aug; 29(8):1374-83. PubMed ID: 16131844
[TBL] [Abstract][Full Text] [Related]
23. Enhanced calcium release in the acute neuronopathic form of Gaucher disease.
Pelled D; Trajkovic-Bodennec S; Lloyd-Evans E; Sidransky E; Schiffmann R; Futerman AH
Neurobiol Dis; 2005 Feb; 18(1):83-8. PubMed ID: 15649698
[TBL] [Abstract][Full Text] [Related]
24. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease.
van Weely S; Brandsma M; Strijland A; Tager JM; Aerts JM
Biochim Biophys Acta; 1993 Mar; 1181(1):55-62. PubMed ID: 8457606
[TBL] [Abstract][Full Text] [Related]
25. Chemical inhibition of β-glucocerebrosidase does not affect phagocytosis and early containment of Leishmania by murine macrophages.
Ribeiro H; Rocha MI; Castro H; Macedo MF
Exp Parasitol; 2020 Sep; 216():107939. PubMed ID: 32535115
[TBL] [Abstract][Full Text] [Related]
26. Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.
Zigdon H; Meshcheriakova A; Farfel-Becker T; Volpert G; Sabanay H; Futerman AH
FEBS Lett; 2017 Mar; 591(5):774-783. PubMed ID: 28186340
[TBL] [Abstract][Full Text] [Related]
27. Neuronal forms of Gaucher disease.
Vitner EB; Futerman AH
Handb Exp Pharmacol; 2013; (216):405-19. PubMed ID: 23563668
[TBL] [Abstract][Full Text] [Related]
28. Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.
Elleder M
J Inherit Metab Dis; 2006 Dec; 29(6):707-15. PubMed ID: 17080304
[TBL] [Abstract][Full Text] [Related]
29. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease.
Aerts JM; Donker-Koopman WE; Koot M; Barranger JA; Tager JM; Schram AW
Clin Chim Acta; 1986 Jul; 158(2):155-63. PubMed ID: 2943536
[TBL] [Abstract][Full Text] [Related]
30. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
Mucci JM; Suqueli García F; de Francesco PN; Ceci R; Di Genaro S; Fossati CA; Delpino MV; Rozenfeld PA
Gene; 2013 Dec; 532(2):186-91. PubMed ID: 24076352
[TBL] [Abstract][Full Text] [Related]
31. Glucocerebroside storage in normal monocyte cultures.
Hardy B; Teitelman-Weissman B; Chazan S; Neri A
Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
[TBL] [Abstract][Full Text] [Related]
32. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition.
Yatziv S; Newburg DS; Livni N; Barfi G; Kolodny EH
J Lab Clin Med; 1988 Apr; 111(4):416-20. PubMed ID: 3351378
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Noelker C; Lu L; Höllerhage M; Vulinovic F; Sturn A; Roscher R; Höglinger GU; Hirsch EC; Oertel WH; Alvarez-Fischer D; Andreas H
J Neurol Sci; 2015 Sep; 356(1-2):129-36. PubMed ID: 26104567
[TBL] [Abstract][Full Text] [Related]
34. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms.
Lloyd-Evans E; Pelled D; Riebeling C; Bodennec J; de-Morgan A; Waller H; Schiffmann R; Futerman AH
J Biol Chem; 2003 Jun; 278(26):23594-9. PubMed ID: 12709427
[TBL] [Abstract][Full Text] [Related]
35. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.
Schueler UH; Kolter T; Kaneski CR; Zirzow GC; Sandhoff K; Brady RO
J Inherit Metab Dis; 2004; 27(5):649-58. PubMed ID: 15669681
[TBL] [Abstract][Full Text] [Related]
36. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
[TBL] [Abstract][Full Text] [Related]
37. Direct activation of microglia by β-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease.
Shimizu T; Schutt CR; Izumi Y; Tomiyasu N; Omahdi Z; Kano K; Takamatsu H; Aoki J; Bamba T; Kumanogoh A; Takao M; Yamasaki S
Immunity; 2023 Feb; 56(2):307-319.e8. PubMed ID: 36736320
[TBL] [Abstract][Full Text] [Related]
38. Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase.
Hayashi Y; Okino N; Kakuta Y; Shikanai T; Tani M; Narimatsu H; Ito M
J Biol Chem; 2007 Oct; 282(42):30889-900. PubMed ID: 17595169
[TBL] [Abstract][Full Text] [Related]
39. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
40. Gaucher disease: pathological mechanisms and modern management.
Jmoudiak M; Futerman AH
Br J Haematol; 2005 Apr; 129(2):178-88. PubMed ID: 15813845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
